Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879404 | 0.88 | TSHR (0.78) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL13879415 | 0.85 | RAB9A (0.79) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL13879530 | 0.83 | RAB9A (0.76) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL23657643 | 0.82 | RAB9A (0.74) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL13879458 | 0.80 | ALDH1A1 (0.70) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL6769387 | 0.77 | RAB9A (0.67) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL6769384 | 0.77 | RAB9A (0.67) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL13879554 | 0.76 | TSHR (0.61) | TSHRALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL13879538 | 0.75 | ALDH1A1 (0.75) | TSHRRAB9AALDH1A1HTTGRM4 | |
| SCHEMBL13879514 | 0.75 | ALDH1A1 (0.60) | TSHRALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TSHR 4851/4885RAB9A 3148/4885ALDH1A1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.